Sex Hormone Receptors in Breast Cancer

Vitamins and Hormones

Volumn 93, Issue , 2013, Pages 99-133

  D'Abreo, Nina ^a,b   Hindenburg, Alexander A ^a,b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

Breast cancer; Endocrine resistance; ER ; ER ; Estrogen receptors

Indexed keywords

EID: 84880272602     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-416673-8.00001-0     Document Type: Chapter

References (190)

1. Ali S., Buluwela L., Coombes R.C. Antiestrogens and their therapeutic applications in breast cancer and other diseases. Annual Review of Medicine 2011, 62:217-232.
2. Ali S., Coombes R.C. Endocrine-responsive breast cancer and strategies for combating resistance. Nature Reviews. Cancer 2002, 2(2):101-112.
3. Allen E., Doisy E.A. Landmark article Sept 8, 1923. An ovarian hormone. Preliminary report on its localization, extraction and partial purification, and action in test animals. By Edgar Allen and Edward A. Doisy. Journal of the American Medical Association 1983, 250(19):2681-2683.
4. Ariazi E.A., Clark G.M., Mertz J.E. Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Research 2002, 62(22):6510-6518.
5. Aronica S.M., Kraus W.L., Katzenellenbogen B.S. Estrogen action via the cAMP signaling pathway: Stimulation of adenylate cyclase and cAMP-regulated gene transcription. Proceedings of the National Academy of Sciences of the United States of America 1994, 91(18):8517-8521.
6. Asselin-Labat M.L., Shackleton M., Stingl J., Vaillant F., Forrest N.C., Eaves C.J., et al. Steroid hormone receptor status of mouse mammary stem cells. Journal of the National Cancer Institute 2006, 98(14):1011-1014.
7. Bannister A.J., Kouzarides T. The CBP co-activator is a histone acetyltransferase. Nature 1996, 384(6610):641-643.
8. Bardou V.J., Arpino G., Elledge R.M., Osborne C.K., Clark G.M. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. Journal of Clinical Oncology 2003, 21(10):1973-1979.
9. Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. The New England Journal of Medicine 2012, 366(6):520-529.
10. Baselga J., Semiglazov V., van Dam P., Manikhas A., Bellet M., Mayordomo J., et al. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer. Journal of Clinical Oncology 2009, 27(16):2630-2637.
11. Beato M. Gene regulation by steroid hormones. Cell 1989, 56(3):335-344.
12. Beatson C.T. On treatment of inoperable cases of the mamma: Suggestions for a new method of treatment with illustrative cases. The Lancet 1896, 2:104-107.
13. Beatson C.T. On treatment of inoperable cases of the mamma: Suggestions for a new method of treatment with illustrative cases. The Lancet 1896, 2:162-165.
14. Beekman J.M., Allan G.F., Tsai S.Y., Tsai M.J., O'Malley B.W. Transcriptional activation by the estrogen receptor requires a conformational change in the ligand binding domain. Molecular Endocrinology 1993, 7(10):1266-1274.
15. Beeram M., Tan Q.T., Tekmal R.R., Russell D., Middleton A., DeGraffenried L.A. Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling. Annals of Oncology 2007, 18(8):1323-1328.
16. Benhar M., Engelberg D., Levitzki A. ROS, stress-activated kinases and stress signaling in cancer. EMBO Reports 2002, 3(5):420-425.
17. Berstein L.M., Wang J.P., Zheng H., Yue W., Conaway M., Santen R.J. Long-term exposure to tamoxifen induces hypersensitivity to estradiol. Clinical Cancer Research 2004, 10(4):1530-1534.
18. Bjornstrom L., Kilic E., Norman M., Parker M.G., Sjoberg M. Cross-talk between Stat5b and estrogen receptor-alpha and -beta in mammary epithelial cells. Journal of Molecular Endocrinology 2001, 27(1):93-106.
19. Bjornstrom L., Sjoberg M. Mechanisms of estrogen receptor signaling: Convergence of genomic and nongenomic actions on target genes. Molecular Endocrinology 2005, 19(4):833-842.
20. Blobel G.A., Sieff C.A., Orkin S.H. Ligand-dependent repression of the erythroid transcription factor GATA-1 by the estrogen receptor. Molecular and Cellular Biology 1995, 15(6):3147-3153.
21. Boyd S. On Oophorectomy in the treatment of cancer. British Medical Journal 1897, 2(1918):890-896.
22. Boyd S. Remarks on Oophorectomy in the treatment of cancer of the breast. British Medical Journal 1899, 1(1988):257-262.
23. Boyd S. On Oophorectomy in cancer of the breast. British Medical Journal 1900, 2:1161-1167.
24. Campbell R.A., Bhat-Nakshatri P., Patel N.M., Constantinidou D., Ali S., Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: A new model for anti-estrogen resistance. Journal of Biological Chemistry 2001, 276(13):9817-9824.
25. Chambliss K.L., Yuhanna I.S., Mineo C., Liu P., German Z., Sherman T.S., et al. Estrogen receptor alpha and endothelial nitric oxide synthase are organized into a functional signaling module in caveolae. Circulation Research 2000, 87(11):E44-E52.
26. Chung Y.L., Sheu M.L., Yang S.C., Lin C.H., Yen S.H. Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. International Journal of Cancer 2002, 97(3):306-312.
27. Clarke R.B., Howell A., Potten C.S., Anderson E. Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Research 1997, 57(22):4987-4991.
28. Colditz G.A. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. Journal of the National Cancer Institute 1998, 90(11):814-823.
29. Cole M.P., Jones C.T., Todd I.D. A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. British Journal of Cancer 1971, 25(2):270-275.
30. Colleoni M. OT2-02-01: The SOLE Trial: International Breast Cancer Study Group (IBCSG 35-07) and Breast International Group (BIG 1-07) Study of Letrozole Extension. Cancer Research 2011, 71(Suppl. 24):610s-611s.
31. Conneely O.M., Jericevic B.M., Lydon J.P. Progesterone receptors in mammary gland development and tumorigenesis. Journal of Mammary Gland Biology and Neoplasia 2003, 8(2):205-214.
32. Couse J.F., Korach K.S. Estrogen receptor null mice: What have we learned and where will they lead us?. Endocrine Reviews 1999, 20(3):358-417.
33. Cowley S.M., Hoare S., Mosselman S., Parker M.G. Estrogen receptors alpha and beta form heterodimers on DNA. Journal of Biological Chemistry 1997, 272(32):19858-19862.
34. Cui X., Schiff R., Arpino G., Osborne C.K., Lee A.V. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. Journal of Clinical Oncology 2005, 23(30):7721-7735.
35. Cuzick J., Sestak I., Baum M., Buzdar A., Howell A., Dowsett M., et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. The Lancet Oncology 2010, 11(12):1135-1141.
36. Davies C., Pan H., Godwin J., Gray R., Arriagada R., Raina V., et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. The Lancet 2013, 381(9869):805-816.
37. de Leeuw R., Neefjes J., Michalides R. A role for estrogen receptor phosphorylation in the resistance to tamoxifen. International Journal of Breast Cancer 2011, 2011:232435.
38. deGraffenried L.A., Friedrichs W.E., Russell D.H., Donzis E.J., Middleton A.K., Silva J.M., et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clinical Cancer Research 2004, 10(23):8059-8067.
39. Dobrescu A., Chang M., Kirtani V., Turi G.K., Hennawy R., Hindenburg A.A. Study of estrogen receptor and progesterone receptor expression in breast ductal carcinoma in situ by immunohistochemical staining in ER/PgR-negative invasive breast cancer. ISRN Oncology 2011, 2011:673790.
40. EBCTCG Tamoxifen for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. The Lancet 1998, 351(9114):1451-1467.
41. EBCTCG Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. The Lancet 2005, 365(9472):1687-1717.
42. Enmark E., Pelto-Huikko M., Grandien K., Lagercrantz S., Lagercrantz J., Fried G., et al. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. Journal of Clinical Endocrinology and Metabolism 1997, 82(12):4258-4265.
43. Evans R.M. The steroid and thyroid superhormone family. Science 1998, 240:889-895.
44. Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute 1998, 90(18):1371-1388.
45. Flouriot G., Brand H., Denger S., Metivier R., Kos M., Reid G., et al. Identification of a new isoform of the human estrogen receptor-alpha (hER-alpha) that is encoded by distinct transcripts and that is able to repress hER-alpha activation function 1. EMBO Journal 2000, 19(17):4688-4700.
46. Forster C., Makela S., Warri A., Kietz S., Becker D., Hultenby K., et al. Involvement of estrogen receptor beta in terminal differentiation of mammary gland epithelium. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(24):15578-15583.
47. Gee A.C., Carlson K.E., Martini P.G., Katzenellenbogen B.S., Katzenellenbogen J.A. Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor. Molecular Endocrinology 1999, 13(11):1912-1923.
48. Giguere V., Yang N., Segui P., Evans R.M. Identification of a new class of steroid hormone receptors. Nature 1988, 331(6151):91-94.
49. Goss P.E. Letrozole in the extended adjuvant setting: MA.17. Breast Cancer Research and Treatment 2007, 105(Suppl. 1):45-53.
50. Gottardis M.M., Robinson S.P., Satyaswaroop P.G., Jordan V.C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Research 1988, 48(4):812-815.
51. Gottlicher M., Heck S., Herrlich P. Transcriptional cross-talk, the second mode of steroid hormone receptor action. Journal of Molecular Medicine (Berlin) 1998, 76(7):480-489.
52. Gradishar W.J. Tamoxifen-What next?. The Oncologist 2004, 9(4):378-384.
53. Gross G.E., Clark G.M., Chamness G.C., McGuire W.L. Multiple progesterone receptor assays in human breast cancer. Cancer Research 1984, 44(2):836-840.
54. Gruvberger-Saal S.K., Bendahl P.O., Saal L.H., Laakso M., Hegardt C., Eden P., et al. Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clinical Cancer Research 2007, 13(7):1987-1994.
55. Haddow A., Watkinson J.M., Paterson E., Koller P.C. Influence of synthetic oestrogens on advanced malignant disease. British Medical Journal 1944, 2(4368):393-398.
56. Harper M.J., Walpole A.L. A new derivative of triphenylethylene: Effect on implantation and mode of action in rats. Journal of Reproduction and Fertility 1967, 13(1):101-119.
57. Heldring N., Pike A., Andersson S., Matthews J., Cheng G., Hartman J., et al. Estrogen receptors: How do they signal and what are their targets. Physiological Reviews 2007, 87(3):905-931.
58. Hewitt S.C., Harrell J.C., Korach K.S. Lessons in estrogen biology from knockout and transgenic animals. Annual Review of Physiology 2005, 67:285-308.
59. Hopp T.A., Weiss H.L., Hilsenbeck S.G., Cui Y., Allred D.C., Horwitz K.B., et al. Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clinical Cancer Research 2004, 10(8):2751-2760.
60. Horwitz K.B., McGuire W.L. Predicting response to endocrine therapy in human breast cancer: A hypothesis. Science 1975, 189(4204):726-727.
61. Hou Y.F., Yuan S.T., Li H.C., Wu J., Lu J.S., Liu G., et al. ERbeta exerts multiple stimulative effects on human breast carcinoma cells. Oncogene 2004, 23(34):5799-5806.
62. Huggins C., Dao T.L. Adrenalectomy and oophorectomy in treatment of advanced carcinoma of the breast. Journal of the American Medical Association 1953, 151(16):1388-1394.
63. Hyder S.M., Chiappetta C., Stancel G.M. Interaction of human estrogen receptors alpha and beta with the same naturally occurring estrogen response elements. Biochemical Pharmacology 1999, 57(6):597-601.
64. Jeng M.H., Yue W., Eischeid A., Wang J.P., Santen R.J. Role of MAP kinase in the enhanced cell proliferation of long term estrogen deprived human breast cancer cells. Breast Cancer Research and Treatment 2000, 62(3):167-175.
65. Jensen E.V. Steroid hormones, receptors, and antagonists. Annals of the New York Academy of Sciences 1996, 784:1-17.
66. Jensen E.V., Jacobson H.I. Fate of steroid estrogens in target tissues. Biological Activities of Steroids in Relation to Cancer 1960, 61-174. Academic Press, New York. G. Pincus, E.P. Vollmer (Eds.).
67. Johnston S.R., Lu B., Scott G.K., Kushner P.J., Smith I.E., Dowsett M., et al. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clinical Cancer Research 1999, 5(2):251-256.
68. Jordan V.C. Tamoxifen: A most unlikely pioneering medicine. Nature Reviews. Drug Discovery 2003, 2(3):205-213.
69. Jordan V.C. The 38th David A. Karnofsky lecture: The paradoxical actions of estrogen in breast cancer-Survival or death?. Journal of Clinical Oncology 2008, 26(18):3073-3082.
70. Jordan V.C. A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: The origins of targeted therapy and chemoprevention. Cancer Research 2009, 69(4):1243-1254.
71. Jordan V.C., Dix C.J., Allen K.E. The effectiveness of long-term tamoxifen treatment in a laboratory model for adjuvant hormone therapy of breast cancer. Adjuvant Therapy of Cancer 1979, 2:19-26.
72. Jordan V.C., Ford L.G. Paradoxical clinical effect of estrogen on breast cancer risk: A "new" biology of estrogen-induced apoptosis. Cancer Prevention Research (Philadelphia, PA) 2011, 4(5):633-637.
73. Jordan V.C., O'Malley B.W. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer. Journal of Clinical Oncology 2007, 25(36):5815-5824.
74. Jordan V.C., Phelps E., Lindgren J.U. Effects of anti-estrogens on bone in castrated and intact female rats. Breast Cancer Research and Treatment 1987, 10(1):31-35.
75. Kahlert S., Nuedling S., van Eickels M., Vetter H., Meyer R., Grohe C. Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. Journal of Biological Chemistry 2000, 275(24):18447-18453.
76. Katzenellenbogen B.S., Katzenellenbogen J.A. Estrogen receptor transcription and transactivation: Estrogen receptor alpha and estrogen receptor beta: Regulation by selective estrogen receptor modulators and importance in breast cancer. Breast Cancer Research 2000, 2(5):335-344.
77. Kelsey J.L., Gammon M.D., John E.M. Reproductive factors and breast cancer. Epidemiologic Reviews 1993, 15(1):36-47.
78. Khan S.A., Rogers M.A., Khurana K.K., Meguid M.M., Numann P.J. Estrogen receptor expression in benign breast epithelium and breast cancer risk. Journal of the National Cancer Institute 1998, 90(1):37-42.
79. Kirkegaard T., McGlynn L.M., Campbell F.M., Muller S., Tovey S.M., Dunne B., et al. Amplified in breast cancer 1 in human epidermal growth factor receptor-Positive tumors of tamoxifen-treated breast cancer patients. Clinical Cancer Research 2007, 13(5):1405-1411.
80. Klinge C.M., Riggs K.A., Wickramasinghe N.S., Emberts C.G., McConda D.B., Barry P.N., et al. Estrogen receptor alpha 46 is reduced in tamoxifen resistant breast cancer cells and re-expression inhibits cell proliferation and estrogen receptor alpha 66-regulated target gene transcription. Molecular and Cellular Endocrinology 2010, 323(2):268-276.
81. Kos M., Reid G., Denger S., Gannon F. Minireview: Genomic organization of the human ERalpha gene promoter region. Molecular Endocrinology 2001, 15(12):2057-2063.
82. Kraus W.L., Montano M.M., Katzenellenbogen B.S. Cloning of the rat progesterone receptor gene 5'-region and identification of two functionally distinct promoters. Molecular Endocrinology 1993, 7(12):1603-1616.
83. Kuiper G.G., Enmark E., Pelto-Huikko M., Nilsson S., Gustafsson J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proceedings of the National Academy of Sciences of the United States of America 1996, 93(12):5925-5930.
84. Kuiper G.G., Lemmen J.G., Carlsson B., Corton J.C., Safe S.H., van der Saag P.T., et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998, 139(10):4252-4263.
85. Kumar P., Wu Q., Chambliss K.L., Yuhanna I.S., Mumby S.M., Mineo C., et al. Direct interactions with G alpha i and G betagamma mediate nongenomic signaling by estrogen receptor alpha. Molecular Endocrinology 2007, 21(6):1370-1380.
86. Kurokawa H., Arteaga C.L. ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clinical Cancer Research 2003, 9(1 Pt. 2):511S-515S.
87. Kushner P.J., Agard D.A., Greene G.L., Scanlan T.S., Shiau A.K., Uht R.M., et al. Estrogen receptor pathways to AP-1. The Journal of Steroid Biochemistry and Molecular Biology 2000, 74(5):311-317.
88. LaCroix A.Z., Chlebowski R.T., Manson J.E., Aragaki A.K., Johnson K.C., Martin L., et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: A randomized controlled trial. Journal of the American Medical Association 2011, 305(13):1305-1314.
89. Lavinsky R.M., Jepsen K., Heinzel T., Torchia J., Mullen T.M., Schiff R., et al. Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proceedings of the National Academy of Sciences of the United States of America 1998, 95(6):2920-2925.
90. Lazennec G., Bresson D., Lucas A., Chauveau C., Vignon F. ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 2001, 142(9):4120-4130.
91. Le Romancer M., Poulard C., Cohen P., Sentis S., Renoir J.M., Corbo L. Cracking the estrogen receptor's posttranslational code in breast tumors. Endocrine Reviews 2011, 32(5):597-622.
92. Lee H., Bai W. Regulation of estrogen receptor nuclear export by ligand-induced and p38-mediated receptor phosphorylation. Molecular and Cellular Biology 2002, 22(16):5835-5845.
93. Lemonick M.D., Park A. New hope for cancer. Time 2001, 157(21):62-69.
94. Lerner L.J., Holthaus F.J., Thompson C.R. A non-steroidal estrogen antiagonist 1-(p-2-diethylaminoethoxyphenyl)-1-phenyl-2-p-methoxyphenyl ethanol. Endocrinology 1958, 63(3):295-318.
95. Levin E.R. Membrane oestrogen receptor alpha signalling to cell functions. The Journal of Physiology 2009, 587(Pt. 21):5019-5023.
96. Levin E.R., Pietras R.J. Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Research and Treatment 2008, 108(3):351-361.
97. Levy N., Tatomer D., Herber C.B., Zhao X., Tang H., Sargeant T., et al. Differential regulation of native estrogen receptor-regulatory elements by estradiol, tamoxifen, and raloxifene. Molecular Endocrinology 2008, 22(2):287-303.
98. Lewis J.S., Osipo C., Meeke K., Jordan V.C. Estrogen-induced apoptosis in a breast cancer model resistant to long-term estrogen withdrawal. The Journal of Steroid Biochemistry and Molecular Biology 2005, 94(1-3):131-141.
99. Lewis-Wambi J.S., Jordan V.C. Estrogen regulation of apoptosis: How can one hormone stimulate and inhibit?. Breast Cancer Research 2009, 11(3):206.
100. Li Y., Lambert M.H., Xu H.E. Activation of nuclear receptors: A perspective from structural genomics. Structure 2003, 11(7):741-746.
101. Liu M.M., Albanese C., Anderson C.M., Hilty K., Webb P., Uht R.M., et al. Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. Journal of Biological Chemistry 2002, 277(27):24353-24360.
102. Liu S., Ginestier C., Charafe-Jauffret E., Foco H., Kleer C.G., Merajver S.D., et al. BRCA1 regulates human mammary stem/progenitor cell fate. Proceedings of the National Academy of Sciences of the United States of America 2008, 105(5):1680-1685.
103. Liu S., Wicha M.S. Targeting breast cancer stem cells. Journal of Clinical Oncology 2010, 28(25):4006-4012.
104. Long B.J., Jelovac D., Handratta V., Thiantanawat A., MacPherson N., Ragaz J., et al. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. Journal of the National Cancer Institute 2004, 96(6):456-465.
105. Lorenzo J. A new hypothesis for how sex steroid hormones regulate bone mass. The Journal of Clinical Investigation 2003, 111(11):1641-1643.
106. Love R.R., Philips J. Oophorectomy for breast cancer: History revisited. Journal of the National Cancer Institute 2002, 94(19):1433-1434.
107. Lu D., Kiriyama Y., Lee K.Y., Giguere V. Transcriptional regulation of the estrogen-inducible pS2 breast cancer marker gene by the ERR family of orphan nuclear receptors. Cancer Research 2001, 61(18):6755-6761.
108. Lu Q., Pallas D.C., Surks H.K., Baur W.E., Mendelsohn M.E., Karas R.H. Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(49):17126-17131.
109. Lubahn D.B., Moyer J.S., Golding T.S., Couse J.F., Korach K.S., Smithies O. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proceedings of the National Academy of Sciences of the United States of America 1993, 90(23):11162-11166.
110. Magee P.J., Rowland I.R. Phyto-oestrogens, their mechanism of action: Current evidence for a role in breast and prostate cancer. British Journal of Nutrition 2004, 91(4):513-531.
111. Mamounas E.P. Adjuvant exemestane therapy after 5 years of tamoxifen: Rationale for the NSABP B-33 trial. Oncology (Williston Park) 2001, 15(5 Suppl. 7):35-39.
112. Martinez-Climent J.A., Andreu E.J., Prosper F. Somatic stem cells and the origin of cancer. Clinical and Translational Oncology 2006, 8(9):647-663.
113. Massarweh S., Osborne C.K., Creighton C.J., Qin L., Tsimelzon A., Huang S., et al. Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Research 2008, 68(3):826-833.
114. Mauriac L., Pippen J.E., Quaresma Albano J., Gertler S.Z., Osborne C.K. Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: Combined results from two multicentre trials. European Journal of Cancer 2003, 39(9):1228-1233.
115. McDonnell D.P., Norris J.D. Connections and regulation of the human estrogen receptor. Science 2002, 296(5573):1642-1644.
116. McGuire W.L., Chamness G.C., Fuqua S.A. Estrogen receptor variants in clinical breast cancer. Molecular Endocrinology 1991, 5(11):1571-1577.
117. McKenna N.J., Lanz R.B., O'Malley B.W. Nuclear receptor coregulators: Cellular and molecular biology. Endocrine Reviews 1999, 20(3):321-344.
118. Mehta R.S., Barlow W.E., Albain K.S., Vandenberg T.A., Dakhil S.R., Tirumali N.R., et al. Combination anastrozole and fulvestrant in metastatic breast cancer. The New England Journal of Medicine 2012, 367(5):435-444.
119. Menasce L.P., White G.R., Harrison C.J., Boyd J.M. Localization of the estrogen receptor locus (ESR) to chromosome 6q25.1 by FISH and a simple post-FISH banding technique. Genomics 1995, 17:263-265.
120. Migliaccio A., Castoria G., Di Domenico M., de Falco A., Bilancio A., Lombardi M., et al. Steroid-induced androgen receptor-oestradiol receptor beta-Src complex triggers prostate cancer cell proliferation. EMBO Journal 2000, 19(20):5406-5417.
121. Migliaccio A., Di Domenico M., Castoria G., de Falco A., Bontempo P., Nola E., et al. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO Journal 1996, 15(6):1292-1300.
122. Migliaccio A., Piccolo D., Castoria G., Di Domenico M., Bilancio A., Lombardi M., et al. Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO Journal 1998, 17(7):2008-2018.
123. Miodini P., Fioravanti L., Di Fronzo G., Cappelletti V. The two phyto-oestrogens genistein and quercetin exert different effects on oestrogen receptor function. British Journal of Cancer 1999, 80(8):1150-1155.
124. Mosselman S., Polman J., Dijkema R. ER beta: Identification and characterization of a novel human estrogen receptor. FEBS Letters 1996, 392(1):49-53.
125. Murphy L.C., Leygue E. The role of estrogen receptor-beta in breast cancer. Seminars in Reproductive Medicine 2012, 30(1):5-13.
126. Nilsson S., Makela S., Treuter E., Tujague M., Thomsen J., Andersson G., et al. Mechanisms of estrogen action. Physiological Reviews 2001, 81(4):1535-1565.
127. Ochnik A.M., Yee D. Estrogen-related receptor alpha: An orphan finds a family. Breast Cancer Research 2012, 14(3):309.
128. Ogawa S., Inoue S., Watanabe T., Orimo A., Hosoi T., Ouchi Y., et al. Molecular cloning and characterization of human estrogen receptor betacx: A potential inhibitor of estrogen action in human. Nucleic Acids Research 1998, 26(15):3505-3512.
129. Ordonez-Moran P., Munoz A. Nuclear receptors: Genomic and non-genomic effects converge. Cell Cycle 2009, 8(11):1675-1680.
130. Osborne M.P. Hormonal intervention in breast cancer. Past, present, and future. Annals of the New York Academy of Sciences 1996, 784:427-432.
131. Osborne C.K., Bardou V., Hopp T.A., Chamness G.C., Hilsenbeck S.G., Fuqua S.A., et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. Journal of the National Cancer Institute 2003, 95(5):353-361.
132. Osborne C.K., Coronado-Heinsohn E.B., Hilsenbeck S.G., McCue B.L., Wakeling A.E., McClelland R.A., et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. Journal of the National Cancer Institute 1995, 87(10):746-750.
133. Osborne C.K., Schiff R. Mechanisms of endocrine resistance in breast cancer. Annual Review of Medicine 2011, 62:233-247.
134. Osipo C., Gajdos C., Liu H., Chen B., Jordan V.C. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. Journal of the National Cancer Institute 2003, 95(21):1597-1608.
135. Paech K., Webb P., Kuiper G.G., Nilsson S., Gustafsson J., Kushner P.J., et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997, 277(5331):1508-1510.
136. Pappas T.C., Gametchu B., Watson C.S. Membrane estrogen receptors identified by multiple antibody labeling and impeded-ligand binding. The FASEB Journal 1995, 9(5):404-410.
137. Paruthiyil S., Parmar H., Kerekatte V., Cunha G.R., Firestone G.L., Leitman D.C. Estrogen receptor beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Research 2004, 64(1):423-428.
138. Pedram A., Razandi M., Wallace D.C., Levin E.R. Functional estrogen receptors in the mitochondria of breast cancer cells. Molecular Biology of the Cell 2006, 17(5):2125-2137.
139. Peter M.E., Krammer P.H. The CD95(APO-1/Fas) DISC and beyond. Cell Death and Differentiation 2003, 10(1):26-35.
140. Pettersson K., Delaunay F., Gustafsson J.A. Estrogen receptor beta acts as a dominant regulator of estrogen signaling. Oncogene 2000, 19(43):4970-4978.
141. Phillips K., Kiely B.E., Francis P.A., Boyle F.M., Fox S.B., Murphy L., et al. ANZ1001 SORBET: Study of estrogen receptor beta and efficacy of tamoxifen, a single arm, phase II study of the efficacy of tamoxifen in triple-negative but estrogen receptor beta-positive metastatic breast cancer. Journal of Clinical Oncology 2012, 30(Suppl.). abstr TPS1136.
142. Prossnitz E.R., Arterburn J.B., Sklar L.A. GPR30: A G protein-coupled receptor for estrogen. Molecular and Cellular Endocrinology 2007, 265-266:138-142.
143. Quaedackers M.E., van den Brink C.E., van der Saag P.T., Tertoolen L.G. Direct interaction between estrogen receptor alpha and NF-kappaB in the nucleus of living cells. Molecular and Cellular Endocrinology 2007, 273(1-2):42-50.
144. Ranhotra H.S. The estrogen-related receptor alpha: The oldest, yet an energetic orphan with robust biological functions. Journal of Receptor and Signal Transduction Research 2010, 30(4):193-205.
145. Ravdin P.M., Green S., Dorr T.M., McGuire W.L., Fabian C., Pugh R.P., et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: Results of a prospective Southwest Oncology Group study. Journal of Clinical Oncology 1992, 10(8):1284-1291.
146. Ray A., Prefontaine K.E., Ray P. Down-modulation of interleukin-6 gene expression by 17 beta-estradiol in the absence of high affinity DNA binding by the estrogen receptor. Journal of Biological Chemistry 1994, 269(17):12940-12946.
147. Razandi M., Oh P., Pedram A., Schnitzer J., Levin E.R. ERs associate with and regulate the production of caveolin: Implications for signaling and cellular actions. Molecular Endocrinology 2002, 16(1):100-115.
148. Robyr D., Wolffe A.P., Wahli W. Nuclear hormone receptor coregulators in action: Diversity for shared tasks. Molecular Endocrinology 2000, 14(3):329-347.
149. Roger P., Sahla M.E., Makela S., Gustafsson J.A., Baldet P., Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Research 2001, 61(6):2537-2541.
150. Russo J., Ao X., Grill C., Russo I.H. Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland. Breast Cancer Research and Treatment 1999, 53(3):217-227.
151. Saphner T., Tormey D.C., Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. Journal of Clinical Oncology 1996, 14(10):2738-2746.
152. Saville B., Wormke M., Wang F., Nguyen T., Enmark E., Kuiper G., et al. Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. Journal of Biological Chemistry 2000, 275(8):5379-5387.
153. Schiff R., Massarweh S.A., Shou J., Bharwani L., Mohsin S.K., Osborne C.K. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clinical Cancer Research 2004, 10(1 Pt. 2):331S-336S.
154. Schinzinger A. Über Carcinoma Mammae. Verhandlungen der Deutschen Gesellschaft für Chirurgie 1889, 18:28-29.
155. Shang Y., Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002, 295(5564):2465-2468.
156. Shoker B.S., Jarvis C., Clarke R.B., Anderson E., Hewlett J., Davies M.P., et al. Estrogen receptor-positive proliferating cells in the normal and precancerous breast. American Journal of Pathology 1999, 155(6):1811-1815.
157. Simoes B.M., Piva M., Iriondo O., Comaills V., Lopez-Ruiz J.A., Zabalza I., et al. Effects of estrogen on the proportion of stem cells in the breast. Breast Cancer Research and Treatment 2011, 129(1):23-35.
158. Simoncini T., Genazzani A.R. Non-genomic actions of sex steroid hormones. European Journal of Endocrinology 2003, 148(3):281-292.
159. Simoncini T., Hafezi-Moghadam A., Brazil D.P., Ley K., Chin W.W., Liao J.K. Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000, 407(6803):538-541.
160. Simoncini T., Rabkin E., Liao J.K. Molecular basis of cell membrane estrogen receptor interaction with phosphatidylinositol 3-kinase in endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology 2003, 23(2):198-203.
161. Sleeman J.P., Cremers N. New concepts in breast cancer metastasis: Tumor initiating cells and the microenvironment. Clinical and Experimental Metastasis 2007, 24(8):707-715.
162. Smith C.L., O'Malley B.W. Coregulator function: A key to understanding tissue specificity of selective receptor modulators. Endocrine Reviews 2004, 25(1):45-71.
163. Song R.X., McPherson R.A., Adam L., Bao Y., Shupnik M., Kumar R., et al. Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation. Molecular Endocrinology 2002, 16(1):116-127.
164. Song R.X., Zhang Z., Santen R.J. Estrogen rapid action via protein complex formation involving ERalpha and Src. Trends in Endocrinology and Metabolism 2005, 16(8):347-353.
165. Speirs V., Skliris G.P., Burdall S.E., Carder P.J. Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. Journal of Clinical Pathology 2002, 55(5):371-374.
166. Stein R.A., McDonnell D.P. Estrogen-related receptor alpha as a therapeutic target in cancer. Endocrine-Related Cancer 2006, 13(Suppl. 1):S25-S32.
167. Stein B., Yang M.X. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta. Molecular and Cellular Biology 1995, 15(9):4971-4979.
168. Stoica G.E., Franke T.F., Wellstein A., Czubayko F., List H.J., Reiter R., et al. Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Molecular Endocrinology 2003, 17(5):818-830.
169. Tee M.K., Rogatsky I., Tzagarakis-Foster C., Cvoro A., An J., Christy R.J., et al. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta. Molecular Biology of the Cell 2004, 15(3):1262-1272.
170. Teyssier C., Belguise K., Galtier F., Chalbos D. Characterization of the physical interaction between estrogen receptor alpha and JUN proteins. Journal of Biological Chemistry 2001, 276(39):36361-36369.
171. Thurlimann B., Keshaviah A., Coates A.S., Mouridsen H., Mauriac L., Forbes J.F., et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. The New England Journal of Medicine 2005, 353(26):2747-2757.
172. Toft D., Gorski J. A receptor molecule for estrogens: Isolation from the rat uterus and preliminary characterization. Proceedings of the National Academy of Sciences of the United States of America 1966, 55(6):1574-1581.
173. Tonetti D.A., Rubenstein R., DeLeon M., Zhao H., Pappas S.G., Bentrem D.J., et al. Stable transfection of an estrogen receptor beta cDNA isoform into MDA-MB-231 breast cancer cells. The Journal of Steroid Biochemistry and Molecular Biology 2003, 87(1):47-55.
174. Torres-Arzayus M.I., Font de Mora J., Yuan J., Vazquez F., Bronson R., Rue M., et al. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 2004, 6(3):263-274.
175. Tremblay A., Tremblay G.B., Labrie F., Giguere V. Ligand-independent recruitment of SRC-1 to estrogen receptor beta through phosphorylation of activation function AF-1. Molecular Cell 1999, 3(4):513-519.
176. Tsai M.J., O'Malley B.W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annual Review of Biochemistry 1994, 63:451-486.
177. Vyhlidal C., Samudio I., Kladde M.P., Safe S. Transcriptional activation of transforming growth factor alpha by estradiol: Requirement for both a GC-rich site and an estrogen response element half-site. Journal of Molecular Endocrinology 2000, 24(3):329-338.
178. Wakeling A.E., Dukes M., Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Research 1991, 51(15):3867-3873.
179. Wang Z., Zhang X., Shen P., Loggie B.W., Chang Y., Deuel T.F. Identification, cloning, and expression of human estrogen receptor-alpha36, a novel variant of human estrogen receptor-alpha66. Biochemical and Biophysical Research Communications 2005, 336(4):1023-1027.
180. Webb P., Lopez G.N., Uht R.M., Kushner P.J. Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens. Molecular Endocrinology 1995, 9(4):443-456.
181. Webb P., Nguyen P., Kushner P.J. Differential SERM effects on corepressor binding dictate ERalpha activity in vivo. Journal of Biological Chemistry 2003, 278(9):6912-6920.
182. Webb P., Nguyen P., Valentine C., Lopez G.N., Kwok G.R., McInerney E., et al. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Molecular Endocrinology 1999, 13(10):1672-1685.
183. White R., Parker M.G. Molecular mechanisms of steroid hormone action. Endocrine-Related Cancer 1998, 5:1-14.
184. Wong C.W., McNally C., Nickbarg E., Komm B.S., Cheskis B.J. Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(23):14783-14788.
185. Yamnik R.L., Digilova A., Davis D.C., Brodt Z.N., Murphy C.J., Holz M.K. S6 kinase 1 regulates estrogen receptor alpha in control of breast cancer cell proliferation. Journal of Biological Chemistry 2009, 284(10):6361-6369.
186. Zhang X.T., Kang L.G., Ding L., Vranic S., Gatalica Z., Wang Z.Y. A positive feedback loop of ER-alpha36/EGFR promotes malignant growth of ER-negative breast cancer cells. Oncogene 2011, 30(7):770-780.
187. Zhao C., Matthews J., Tujague M., Wan J., Strom A., Toresson G., et al. Estrogen receptor beta2 negatively regulates the transactivation of estrogen receptor alpha in human breast cancer cells. Cancer Research 2007, 67(8):3955-3962.
188. Zhou Y., Yau C., Gray J.W., Chew K., Dairkee S.H., Moore D.H., et al. Enhanced NF kappa B and AP-1 transcriptional activity associated with antiestrogen resistant breast cancer. BMC Cancer 2007, 7:59.
189. Zwart W., de Leeuw R., Rondaij M., Neefjes J., Mancini M.A., Michalides R. The hinge region of the human estrogen receptor determines functional synergy between AF-1 and AF-2 in the quantitative response to estradiol and tamoxifen. Journal of Cell Science 2010, 123(Pt. 8):1253-1261.
190. Zwart W., Griekspoor A., Berno V., Lakeman K., Jalink K., Mancini M., et al. PKA-induced resistance to tamoxifen is associated with an altered orientation of ERalpha towards co-activator SRC-1. EMBO Journal 2007, 26(15):3534-3544.